Veraxa Biotech AG - Post de-SPAC (NASDAQ: VRXA) appointed Raju Willener as chief financial officer effective immediately on September 4, 2026. He will serve as the company’s principal financial officer and principal accounting officer, reporting to Chief Executive Officer and Co-Founder Christoph Antz, Ph.D. …
The supplement relates to up to 120,295,385 ordinary shares and up to 6,786,739 private warrants.
Perspective Therapeutics, Inc. (AMEX: CATX) now has Lantheus Holdings (NASDAQ: LNTH) as an activist holder of 10.0% of its Common Stock, equal to 11,440,513 shares. Lantheus Holdings, Lantheus Medical Imaging and Lantheus Alpha are the reporting persons connected with the position. The three entities …
The financing includes $75 million funded at closing and gives Intellia (NASDAQ: NTLA) access to additional capital tied to regulatory, revenue and equity milestones.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is asking stockholders to raise its authorized common-stock count from 490,000,000 shares to 675,000,000. The proposed amendment would leave the authorized numbers of non-voting common stock and preferred stock unchanged, while the board would retain discretion over whether to …
Kalinichev Mikhail was awarded 306,765 shares of Addex Therapeutics Ltd. and 200,000 derivative securities on 2 September 2026. The transactions also recorded dispositions of the same respective quantities, with post-transaction ownership listed at 306,765 shares and 200,000 derivative securities.
Krystal Biotech, Inc. (NASDAQ: KRYS) President and CEO Krishnan Krish S sold 25,000 shares at prices ranging from $354.54 to $366.56 per share. The transactions occurred on Sep. 4, 2026.
Maze Therapeutics, Inc. (NASDAQ: MAZE) shares sold by CSBO Atul Dandekar totaled 6,434 across separate transactions. The sales left Dandekar with 32,316 shares, establishing his reported remaining position after the transactions.
Maze Therapeutics, Inc. (NASDAQ: MAZE) Chief Executive Officer Coloma Jason V sold 22,638 shares, leaving him with 27,362 shares after the transactions. The shares changed hands at prices ranging from $25.77 to $27.12 per share.
Mills Roger, chief medical officer of Addex Therapeutics Ltd. reported an award and disposal involving 392,837 Addex shares on September 2, 2026. His post-transaction shareholding was recorded at 785,976 following the award.